Getting to the heart of PRKAG2 Syndrome.
About the Corventis Ph 1/2 Clinical Trial
The Corventis clinical trial is currently evaluating ATR 1072, an investigational therapy being studied for the treatment of PRKAG2 syndrome.
PRKAG2 syndrome is a rare, inherited heart condition (cardiomyopathy), and ATR 1072 is designed to normalize activity of the PRKAG2 gene in the heart. This is the first investigational therapy designed to address the underlying genetic cause of PRKAG2 syndrome.
The Corventis trial is the first time ATR 1072 is being studied in people. As a Phase 1/2 trial, it is primarily focused on safety, how the body processes the therapy and heart-related measures including imaging, heart rhythm and other study markers. It is a single arm open-label study, which means everyone who takes part receives ATR 1072.
Participating in this clinical trial may or may not help you directly, but it is an important opportunity to contribute to research that may advance the understanding of PRKAG2 syndrome and ATR 1072.
This website is a general overview and isn't a substitute for the information the study team will provide.
Who may be eligible.
A few key criteria help determine whether the study may be a fit. The study team confirms full eligibility during screening.
Adults
You are between 18 and 65 years old.
Confirmed PRKAG2 genetic result
A variant in the PRKAG2 gene associated with certain heart problems. Genetic testing can also occur as a part of screening for the study. You can discuss more information about genetic testing with your doctor directly.
Heart involvement
You have heart characteristics consistent with PRKAG2 syndrome such as increased heart muscle thickness, pre-excitation (aberrant conduction from the atria to the ventricles) on ECG or other findings your cardiologist has discussed with you.
Able to attend study visits
You can travel to a participating site for regularly scheduled appointments through the entire study (at least 1 year).
PRKAG2 variants can run in families and members of the same family can participate in this study.
PRKAG2 syndrome is inherited in an autosomal dominant fashion, which means that if you have PRKAG2 syndrome there may be a 50% chance of passing it on to a child. If someone in your family has a PRKAG2 variant, close relatives may also want to talk with a doctor or genetic counselor about testing and follow-up care. Our patient resources explain genetic testing and what it may mean for you and your family.
What does participation look like.
From first screening to final visit, here’s the path participants follow over approximately two years. The study team guides you through every step.
- 1
Screening
You meet the study site team, review your medical history, complete screening tests, and discuss consent before any study treatment begins.
- 248 weeks
Treatment period
You receive ATR 1072 by IV infusion about every 6 weeks.
- 342 weeks
Long-term extension
After the treatment period, you will continue receiving study drug and have regular visits.
- 4
Follow-ups
After your last dose, the study team continues to monitor your safety and the heart-related measures tracked in the study. Follow-up visits continue through a final extended period before you return to your regular care team.
Travel support and reimbursement for the patient and a caregiver will be provided while participating in the study.
Find a study site near you.
Corventis is opening at sites in the United States and Canada. Use the map or search tool to view sites and find the closest location.
Common questions about Corventis.
Yes. Corventis is a single arm, open-label trial which means everyone who enrolls receives ATR 1072. There is no placebo group. The dose level depends on which study group is open when you enroll.
Still have questions?
Contact the team.
If you, a family member, or a patient may be interested in Corventis, send us a note. A member of our team can follow up with general information about the study.
Please note: We cannot provide medical advice, share another person’s information, or confirm eligibility by email. Eligibility is decided at the study site after screening.